ArticleScientific reports2026
Deep learning based on multiparametric MRI for differentiating benign from malignant PI-RADS 3 prostate lesions: a dual-center study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To address the diagnostic challenge of indeterminate PI-RADS 3 prostate lesions, we developed a non-invasive deep learning radiomics model using multiparametric MRI. This dual-center retrospective study included 382 patients. Lesions on T2WI, DWI, and ADC were segmented and standardized. Deep learning features were extracted via ResNet101, and radiomics features were selected using minimum Redundancy Maximum Relevance (mRMR) and Least Absolute Shrinkage and Selection Operator (LASSO). We built and compared three models: clinical, deep-learning radiomics signature (DLRS), and a combined model. The combined model achieved the highest AUCs (0.951, 0.964, 0.925), significantly outperforming the clinical model (p < 0.05). The DLRS model also showed high performance (AUCs: 0.946, 0.932, 0.918). The nomogram was well-calibrated, and DCA indicated clinical utility. This mpMRI-based deep learning model accurately differentiates malignant from benign PI-RADS 3 lesions, offering a valuable non-invasive tool to aid clinical decisions and reduce unnecessary biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.